Top

Published in:

01-02-2012 | PHASE II STUDIES

Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity

Authors: Seok Jin Kim, Kihyun Kim, Yong Park, Byung Soo Kim, Jooryung Huh, Young Hae Ko, Keunchil Park, Cheolwon Suh, Won Seog Kim

Published in: Investigational New Drugs | Issue 1/2012

Summary

Background There is still no consensus on the role of alemtuzumab as a salvage therapy for relapsed or refractory peripheral T-cell lymphoma (PTCL). We studied the efficacy and toxicity of combination treatment of alemtuzumab, dexamethasone, cytarabine, and cisplatin (A-DHAP) for treating PTCL. Methods We enrolled 24 patients with relapsed or refractory PTCL. Each patient received DHAP plus alemtuzumab every 3 weeks for up to three cycles. Two alemtuzumab dosages of 70 mg or 40 mg were used per cycle. After A-DHAP treatment, the responders underwent autologous stem cell transplantation. Results The overall response rate was 50.0% (12 of 24 patients), including five complete responders and seven partial responders. Analysis of the responses according to histological type showed a higher objective response rate for PTCL-unspecified (69.2%: four complete responders, five partial responders) than for extranodal NK/T cell lymphoma (12.5%, one partial responder). The median overall survival (OS) after enrollment was 6.0 months (95% confidence interval: 4.20–7.80 months), and the median response duration of responders was 2.93 months (95% confidence interval: 0.93–4.93 months). The overall response rate and OS did not differ significantly according to the dosage of alemtuzumab (70 mg vs. 40 mg, P > 0.05). The most frequent side effect was grade 3/4 leukopenia. Non-disease-related death occurred more frequently in patients who received 70 mg of alemtuzumab. Conclusions The combination of alemtuzumab plus DHAP might be effective salvage chemotherapy for PTCL, and 40 mg of alemtuzumab appears to be a more tolerable dosage when used in combination with DHAP.

(1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 89:3909–3918

Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999) The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 10:1419–1432PubMedCrossRef

Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, Cazals-Hatem D, Bosly A, Xerri L, Tilly H, Berger F, Bouhabdallah R, Diebold J (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 92:76–82PubMed

Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, Zaja F, Cortelazzo S, Rigacci L, Devizzi L, Todeschini G, Santini G, Brugiatelli M, Federico M (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474–2479. doi:10.1182/blood-2003-09-3080 PubMedCrossRef

Kim K, Kim WS, Jung CW, Im YH, Kang WK, Lee MH, Park CH, Ko YH, Ree HJ, Park K (2002) Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. Eur J Cancer 38:75–81PubMedCrossRef

Salisbury JR, Rapson NT, Codd JD, Rogers MV, Nethersell AB (1994) Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin’s lymphomas. J Clin Pathol 47:313–317PubMedCrossRef

Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, Schetelig J, Seipelt G, Osterborg A (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103:2920–2924. doi:10.1182/blood-2003-10-3389 PubMedCrossRef

Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, De Sanctis V, Papa G, Martelli MF, Calabresi F, Tura S, Mandelli F (1996) High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin’s lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol 14:534–542PubMed

Olivieri A, Brunori M, Capelli D, Montanari M, Massidda D, Gini G, Lucesole M, Poloni A, Offidani M, Candela M, Centurioni R, Leoni P (2004) Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol 72:10–17. doi:10.1046/j.0902-4441.2004.00171.x PubMedCrossRef

10.

Kim SJ, Kim K, Kim BS, Suh C, Huh J, Ko YH, Kim WS (2009) Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study. Ann Oncol 20:390–392PubMedCrossRef

11.

Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10PubMedCrossRef

12.

Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244PubMed

13.

Blystad AK, Enblad G, Kvaloy S, Berglund A, Delabie J, Holte H, Carlson K, Kvalheim G, Bengtsson M, Hagberg H (2001) High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 27:711–716. doi:10.1038/sj.bmt.1702867 PubMedCrossRef

14.

Huang CL, Lin ZZ, Su IJ, Chao TY, Tien HF, Chang MC, Huang MC, Kao WY, Tang JL, Yeh KH, Wang CH, Hsu CH, Liu MY, Cheng AL (2002) Combination of 13-cis retinoic acid and interferon-alpha in the treatment of recurrent or refractory peripheral T-cell lymphoma. Leuk Lymphoma 43:1415–1420PubMedCrossRef

15.

Park BB, Kim WS, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Jung CW, Park YS, Im YH, Kang WK, Ko YH, Lee MH, Park K (2005) IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas. Leuk Lymphoma 46:1743–1748. doi:10.1080/10428190500178266 PubMedCrossRef

16.

Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, Levis A, Manna A, Secondo V, Rigacci L, Pinto A, Iannitto E, Zoli V, Torchio P, Pileri S, Tarella C (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316–2323. doi:10.1182/blood-2007-02-074641 PubMedCrossRef

17.

Kim JG, Sohn SK, Chae YS, Cho YY, Yang DH, Lee JJ, Kim HJ, Shin HJ, Chung JS, Cho GJ, Lee WS, Joo YD, Sohn CH, Oh SJ (2007) Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 60:129–134. doi:10.1007/s00280-007-0469-9 PubMedCrossRef

18.

Lee Y, Uhm JE, Lee HY, Park MJ, Kim H, Oh SJ, Jang JH, Kim K, Jung CW, Ahn YC, Park K, Ko YH, Kim WS (2009) Clinical features and prognostic factors of patients with “peripheral T cell lymphoma, unspecified”. Ann Hematol 88:111–119. doi:10.1007/s00277-008-0544-2 PubMedCrossRef

19.

Chang ST, Lu CL, Chuang SS (2007) CD52 expression in non-mycotic T- and NK/T-cell lymphomas. Leuk Lymphoma 48:117–121. doi:10.1080/10428190601016167 PubMedCrossRef

20.

Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA (2007) Expression of CD52 in peripheral T-cell lymphoma. Haematologica 92:566–567PubMedCrossRef

21.

Hui D, Lam W, Toze C, Delorme M, Noble M, Klimo P, Sutherland J, Gill K, Connors J, Sehn L (2008) Alemtuzumab in clinical practice: a British Columbia experience. Leuk Lymphoma 49:218–226. doi:10.1080/10428190701760029 PubMedCrossRef

22.

Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554–3561PubMedCrossRef

23.

Lundin J, Porwit-MacDonald A, Rossmann ED, Karlsson C, Edman P, Rezvany MR, Kimby E, Osterborg A, Mellstedt H (2004) Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 18:484–490. doi:10.1038/sj.leu.2403258 PubMedCrossRef

24.

Nosari A, Tedeschi A, Ricci F, Montillo M (2008) Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab. Haematologica 93:e30–31. doi:10.3324/haematol.12465 PubMedCrossRef

Title: Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity
Authors: Seok Jin Kim
Kihyun Kim
Yong Park
Byung Soo Kim
Jooryung Huh
Young Hae Ko
Keunchil Park
Cheolwon Suh
Won Seog Kim
Publication date: 01-02-2012
Publisher: Springer US
Published in: Investigational New Drugs / Issue 1/2012
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-010-9523-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 1/2012

A novel aminosteroid of the 5α-androstane-3α,17β-diol family induces cell cycle arrest and apoptosis in human promyelocytic leukemia HL-60 cells

Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer

Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies

A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma

Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium

The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer